Postmenopausal Hormone Therapy and Atherosclerosis — Time Is of the Essence
Published March 31, 2016
N Engl J Med 2016;374:1279-1280
DOI: 10.1056/NEJMe1602846
Abstract
Multiple prospective cohort studies in the 1980s indicated that hormone therapy was associated with a nearly 50% lower risk of coronary heart disease in postmenopausal women,1 which prompted speculation that such therapy could be used to prevent coronary events. However, subsequent large-scale randomized trials that evaluated the effect of postmenopausal hormone therapy failed to support the presence of a cardiovascular benefit. Among women with established coronary heart disease, combined estrogen–progestin therapy resulted in an increased risk of coronary heart disease events at 1 year and had no significant effects on the risk of coronary heart disease events in longer-term follow-up. . . .
Access this content
Select an option below:
Create your account for free access to subscriber-only content.
Get Free Access Now Subscribe For Full AccessAlready have an account?
Sign In
Print subscriber?
Activate your online access
Interested in purchasing this article?
BUY NOW FOR $55
Are you a member of an institution such as a university or hospital?Learn more about Institutional Access
Notes
Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
Supplementary Material
Disclosure Forms (nejme1602846_disclosures.pdf)
- Download
- 110.87 KB
Information & Authors
Information
Published In
Copyright
Copyright © 2016 Massachusetts Medical Society. All rights reserved.
For personal use only. Any commercial reuse of NEJM Group content requires permission.
History
Published online: March 31, 2016
Published in issue: March 31, 2016
Topics
Authors
Affiliations
From the University of Massachusetts Medical School, Worcester (J.F.K.).
Metrics & Citations
Metrics
Altmetrics
Citations
Export citation
Select the format you want to export the citation of this publication.
Cited by
- Management of Risks Factors for Older Women: Osteoporosis and Cardiovascular Disease (CVD), Handbook of Gynecology, (623-637), (2023).https://doi.org/10.1007/978-3-031-14881-1_47
- Targeting estrogen receptor signaling for treating heart failure, Heart Failure Reviews, 29, 1, (125-131), (2023).https://doi.org/10.1007/s10741-023-10356-9
- Management of Risks Factors for Older Women: Osteoporosis and Cardiovascular Disease (CVD), Handbook of Gynecology, (1-16), (2023).https://doi.org/10.1007/978-3-319-17002-2_47-2
- Sex differences and related estrogenic effects in heart failure with preserved ejection fraction, Heart Failure Reviews, 28, 4, (937-948), (2022).https://doi.org/10.1007/s10741-022-10274-2
- Sexualhormone, Arzneiverordnungs-Report 2021, (745-760), (2021).https://doi.org/10.1007/978-3-662-63825-5_42
- Menopausal hormone therapy and women’s health: An umbrella review, PLOS Medicine, 18, 8, (e1003731), (2021).https://doi.org/10.1371/journal.pmed.1003731
- Estrogen-Mediated Gaseous Signaling Molecules in Cardiovascular Disease, Trends in Endocrinology & Metabolism, 31, 10, (773-784), (2020).https://doi.org/10.1016/j.tem.2020.06.001
- Sexualhormone, Arzneiverordnungs-Report 2020, (833-848), (2020).https://doi.org/10.1007/978-3-662-62168-4_41
- Premature ovarian insufficiency – to treat or not to treat?, Reproductive Endocrinology, 0, 50, (12-16), (2019).https://doi.org/10.18370/2309-4117.2019.50.12-16
- Sexualhormone, Arzneiverordnungs-Report 2019, (979-996), (2019).https://doi.org/10.1007/978-3-662-59046-1_44
- See more
Loading...